Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Minerva Neurosciences announced progress and financial results for Q2 2026, emphasizing its ongoing global Phase 3 trial of roluperidone for treating negative symptoms of schizophrenia. The company remains on track for topline efficacy data expected in the second half of 2027. Increased R&D and administrative expenses reflect trial activities. The …